ETF Holdings Breakdown of CABA
| Stock Name | Cabaletta Bio Inc |
| Ticker | CABA(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US12674W1099 |
CABA institutional holdings
The adjusted close for CABA on 2025-12-24 was 2.19
The following institutional investment holdings of CABA have been identified
Book value of shares is calculated on the adjusted close price of each day (row).News associated with CABA
- Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of “Buy” from Analysts
- Shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) have been assigned an average recommendation of “Buy” from the eight analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy […] - 2025-08-06 03:06:51
- Brokerages Set Cabaletta Bio, Inc. (NASDAQ:CABA) PT at $20.33
- Shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) have received an average rating of “Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-06-20 02:52:50
- Two Sigma Investments LP Buys 331,417 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)
- Two Sigma Investments LP boosted its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 78.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 751,894 shares of the company’s stock after acquiring an additional 331,417 shares during the quarter. Two Sigma Investments LP’s holdings in Cabaletta Bio were worth $1,707,000 […] - 2025-06-03 04:48:49
- Two Sigma Advisers LP Has $1.89 Million Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA)
- Two Sigma Advisers LP grew its holdings in shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 195.8% in the 4th quarter, Holdings Channel reports. The fund owned 831,900 shares of the company’s stock after buying an additional 550,700 shares during the period. Two Sigma Advisers LP’s holdings in Cabaletta Bio were worth $1,888,000 […] - 2025-05-30 04:50:52
- Contrasting Cabaletta Bio (NASDAQ:CABA) & Genocea Biosciences (NASDAQ:GNCA)
- Cabaletta Bio (NASDAQ:CABA – Get Free Report) and Genocea Biosciences (NASDAQ:GNCA – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings. Institutional and Insider Ownership 0.6% of Genocea […] - 2025-05-30 02:45:04
- Citigroup Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $13.00
- Cabaletta Bio (NASDAQ:CABA – Free Report) had its target price trimmed by Citigroup from $17.00 to $13.00 in a research report report published on Friday,Benzinga reports. The firm currently has a buy rating on the stock. Other equities analysts have also recently issued research reports about the company. Guggenheim raised their price target on Cabaletta […] - 2025-05-19 02:30:50
- Pre-Market Most Active for May 16, 2025 : TSLL, INZY, NVDA, SQQQ, ACHR, CABA, TQQQ, NVO, SPCE, UNH, QBTS, NIO
- The NASDAQ 100 Pre-Market Indicator is up 57.92 to 21,393.74. The total Pre-Market volume is currently 272,014,558 shares traded.The following are the most active stocks for the pre-market session: Direxion Daily TSLA Bull 2X Shares (TSLL) is +0.43 at $15.25, with 15,512,189 sha - 2025-05-16 09:28:53
- 41,626 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Purchased by Stifel Financial Corp
- Stifel Financial Corp acquired a new position in Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) during the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 41,626 shares of the company’s stock, valued at approximately $94,000. Other large investors have also modified their holdings of the company. Renaissance Technologies LLC bought a new position in Cabaletta […] - 2025-05-16 04:28:58
- Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Bought by Barclays PLC
- Barclays PLC raised its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 17.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 71,617 shares of the company’s stock after buying an additional 10,487 shares during the period. Barclays PLC’s holdings in Cabaletta Bio […] - 2025-05-14 05:04:50
- Wells Fargo & Company MN Acquires 16,250 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)
- Wells Fargo & Company MN raised its holdings in shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 67.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 40,412 shares of the company’s stock after acquiring an additional 16,250 shares during the period. […] - 2025-05-13 04:17:00
- Federated Hermes Inc. Purchases 146,959 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)
- Federated Hermes Inc. grew its position in Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 37,876.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 147,347 shares of the company’s stock after buying an additional 146,959 shares during the period. Federated Hermes Inc.’s holdings in Cabaletta Bio were worth $334,000 as of its most […] - 2025-04-18 05:34:53
- Cabaletta Bio (NASDAQ:CABA) Earns Buy Rating from Guggenheim
- Cabaletta Bio (NASDAQ:CABA – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Guggenheim in a research note issued on Tuesday,Benzinga reports. They presently have a $23.00 price objective on the stock. A number of other analysts have also recently weighed in on the stock. Wells Fargo & Company cut shares […] - 2025-04-03 04:40:57
- Wells Fargo & Company Has Lowered Expectations for Cabaletta Bio (NASDAQ:CABA) Stock Price
- Cabaletta Bio (NASDAQ:CABA – Get Free Report) had its target price dropped by research analysts at Wells Fargo & Company from $6.00 to $3.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 141.94% […] - 2025-04-03 02:48:48
- Charles Schwab Investment Management Inc. Sells 16,585 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)
- Charles Schwab Investment Management Inc. cut its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 13.2% during the 4th quarter, Holdings Channel reports. The firm owned 109,260 shares of the company’s stock after selling 16,585 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Cabaletta Bio were worth $248,000 […] - 2025-04-02 06:14:56
- HC Wainwright Reiterates Buy Rating for Cabaletta Bio (NASDAQ:CABA)
- HC Wainwright reaffirmed their buy rating on shares of Cabaletta Bio (NASDAQ:CABA – Free Report) in a report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $25.00 price target on the stock. A number of other equities analysts also recently commented on CABA. Wells Fargo & Company downgraded shares of Cabaletta Bio from […] - 2025-04-02 05:16:58
- UBS Group Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $7.00
- Cabaletta Bio (NASDAQ:CABA – Free Report) had its price target reduced by UBS Group from $10.00 to $7.00 in a report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock. CABA has been the subject of a number of other research reports. Evercore ISI downgraded Cabaletta Bio from an “outperform” […] - 2025-04-02 04:38:50
- Cabaletta Bio (NASDAQ:CABA) versus Outlook Therapeutics (NASDAQ:OTLK) Head to Head Survey
- Cabaletta Bio (NASDAQ:CABA – Get Free Report) and Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends. Analyst Recommendations This is a summary of […] - 2025-03-24 04:24:53
- Critical Analysis: Cabaletta Bio (NASDAQ:CABA) & Arcellx (NASDAQ:ACLX)
- Cabaletta Bio (NASDAQ:CABA – Get Free Report) and Arcellx (NASDAQ:ACLX – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership. Analyst Ratings This is a breakdown of recent ratings […] - 2025-03-10 04:24:50
- HC Wainwright Reaffirms Buy Rating for Cabaletta Bio (NASDAQ:CABA)
- Cabaletta Bio (NASDAQ:CABA – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $25.00 target price on the stock. A number of other brokerages have also recently weighed in on CABA. TD Cowen raised Cabaletta Bio to a “strong-buy” […] - 2025-02-20 05:04:50
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.
Copyright Market Footprint Ltd. Privacy Policy
0.5%